Protagonist Therapeutics, Inc. (PTGX) Q4 2019 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Up 1.46%

Protagonist Therapeutics reported a loss per share of $0.63, but the stock rose by 1.46%. Investors may be reacting positively to management's comments about ongoing clinical trials and potential future data releases, despite the lack of revenue information and guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.63	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about their clinical developments. They are focused on upcoming data that could impact future growth.

Management highlighted ongoing progress in clinical trials.

They emphasized the importance of upcoming data releases.

There was a focus on maintaining operational efficiency.

Protagonist Therapeutics Misses on EPS, Stock Up 1.46%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Up 1.46%

Key numbers

Management commentary